A PD-1 high CD4 + T Cell Population With a Cytotoxic Phenotype is Associated With Interstitial Lung Disease in Systemic Sclerosis.

Objective: T cells contribute to tissue injury in systemic sclerosis (SSc), yet the specific T cell subsets expanded in patients with SSc remain incompletely defined. Here we evaluated specific phenotypes and functions of peripheral helper T (Tph) and follicular helper T (Tfh) cells, which have been implicated in autoantibody production, and assessed their associations with clinical features in a well-characterized cohort of patients with SSc.
Methods: Mass cytometry of T cells from peripheral blood mononuclear cells of patients with SSc and controls were evaluated using t-distributed stochastic neighbor embedding visualization, biaxial gating, and marker expression levels. Findings were validated with flow cytometry and in vitro assays.
Results: The frequencies of PD-1 ^high CXCR5 ⁺ Tfh cells and PD-1 ^high CXCR5 ^- Tph cells were similar in patients with SSc and controls. t-distributed stochastic neighbor embedding visualization (tSNE) revealed distinct populations within the PD-1 ^high CXCR5 ^- cells distinguished by expression of HLA-DR and inducible costimulator (ICOS). Among PD-1 ^high CXCR5 ^- cells, only the HLA-DR ⁺ ICOS ^- cell population was expanded in patients with SSc. Cytometric and RNA sequencing analyses indicated that these cells expressed cytotoxic rather than B cell helper features. HLA-DR ⁺ ICOS ^- PD-1 ^high CXCR5 ^- cells were less potent in inducing B cell plasmablast differentiation and antibody production than comparator T helper cell populations. HLA-DR ⁺ ICOS ^- PD-1 ^high CXCR5 ^- cells were significantly associated with the presence and severity of interstitial lung disease among patients with SSc.
Conclusion: Among PD-1 ^high CXCR5 ^- T cells, a subset of HLA-DR ⁺ ICOS ^- cells with cytotoxic features is specifically expanded in patients with SSc and is significantly associated with interstitial lung disease severity. This potential cytotoxicity appearing in the CD4 T cell population can be evaluated as a prognostic disease biomarker in patients with SSc.
(© 2024 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)